IMV News and Press, IMV Inc. From 06/12/19

Complete radiologic responses linked to T cell activity observed in two of first six evaluable patients IMV to host investor conference call and webcast on June 12, 2019 at 8:00 am ET IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced up...

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more ...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Wednesday, June 12, 2019, at 8:00 a.m. ET. This call will provide an update on its ongoing pha...

Tumor regressions demonstrate potential for DPX-Survivac immunotherapy in hard-to-treat solid tumors Data correlations of survivin specific T cell levels and durable clinical benefit continue to link novel mechanism of action of DPX-Survivac with anti-cancer activity IMV Inc. (Na...

Company to host conference call following ASCO presentation on June 2 to discuss updated clinical data IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the American Society of Clinical Oncology (ASCO) has published an abstract on t...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in May: RBC Capital Markets Global Healthcare Conference Date : Tuesday, May 21, 2019 ...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company (or the ”Corporation”), today announced the voting results from its Annual and Special Meeting of Shareholders held on Thursday May 9, 2019. Based on the proxies received and the votes on a show o...

IMV (NASDAQ: IMV ): Q1 GAAP EPS of -C$0.13. More news on: IMV Inc., IMV INC, Earnings news and commentary, , Read more ...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2019. “The DPX-Survivac program continues to be a major value-driver for IMV, with its unique mechanism of action pr...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today joins with World Ovarian Cancer Coalition and Ovarian Cancer Canada in recognizing World Ovarian Cancer Day (WOCD). This initiative aims to raise awareness of, and bring hope to, the global challenges...